Atrial Fibrillation (AF)FARA BlockNCT06803238
Procedural Mitral Isthmus Block Durability After Pulsed-Field Ablation in Patients with Non-Paroxysmal Atrial Fibrillation
An observational study of Atrial Fibrillation (AF), run by Charles University, Czech Republic.
Trial summary
Mitral isthmus is one of the targets for the catheter ablation of non-paroxysmal atrial fibrillation (AF), in which pulmonary veins isolation alone is not deemed sufficient. Typically, lateral mitral isthmus ablation line is performed from the mitral annulus to the ostium of the left inferior pulmonary vein or to the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation (AF)
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- Jan 2025to Apr 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients referred for catheter ablation of non paroxysmal AF by referring cardiologists and from arrythmology clinic
Who may be able to join
- adult patients with symptomatic non-paroxysmal atrial fibrillation indicated for catheter ablation according to the current guidelines
Who cannot join
- Contraindication to catheter ablation according to the current guidelines
- previous left atrial ablation
- left ventricular dysfunction with LV EF < 30%
- Patients at high risk of prolonged analgosedation, e.g. history of severe COPD (stage 3 or 4), obstructive sleep apnea on treatment
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Mitral isthmus is one of the targets for the catheter ablation of non-paroxysmal atrial fibrillation (AF), in which pulmonary veins isolation alone is not deemed sufficient. Typically, lateral mitral isthmus ablation line is performed from the mitral annulus to the ostium of the left inferior pulmonary vein or to the posterior base of the left atrial appendage. When conduction block across the mitral isthmus is achieved, the standard practice using radiofrequency energy is to wait 20 minutes to verify durability of the conduction block.
Currently, there is an increase in procedures performed using pulsed-field energy (PF). The procedure is in most centers terminated immediately after the energy is delivered, and, unlike radiofrequency energy procedures, there is no waiting period to see if the conduction through the ablation lines returns. However return of conduction across the mitral isthmus has been described during reablation procedures performed for clinical recurrence of arrhythmia (perimitral flutter or atrial fibrillation).
Read more
The presented study is a follow-up of previous work, which included 30 patients with non-paroxysmal AF, who underwent PF ablation including mitral isthmus ablation as part of the procedure. Ablation of the mitral isthmus was performed by repeated series of 9 PF energy applications. After each series a waiting period of 20 minutes followed. In case of recurrence of conduction, another series of 9 PF applications was delivered followed by a new waiting period. In the cases of reconduction after the 3rd series, one last series of PF applications was performed, where the number of applications was left at the discretion of the operator, where the total number of applications delivered to the mitral isthmus could not exceed 50. We found that although conduction block on the mitral isthmus was achieved in 90 % of patients after all series, it was only in 33,3 % of patients after the first series. Repeated waiting and multiple ablation series prolonged the procedure unnecessarily. On the other hand, a very high number of pulsed-field energy applications applied initially could be associated with a risk of hemolysis. So far, the number of PF applications up to 80-100 were demonstrated to be safe.
This present study aims to determine whether increasing the number of applications in the first series delivered to the mitral isthmus will be associated with faster and durable achievement of conduction block across the mitral isthmus.
A total of 40 patients with symptomatic non-paroxysmal AF, indicated for catheter ablation according to current guidelines, will be included. Patients with previous left atrial ablation, presenting left ventricular dysfunction with LV EF < 30%, as well as patients at high risk of prolonged analgosedation (i.g. history of severe COPD, treated OSA) will be excluded. The procedure will be performed according to the standards of our center, i.e. pulmonary veins isolation, left atrial posterior wall ablation and mitral isthmus ablation will be performed. All procedures will be performed under analgosedation or general anesthesia controlled by an anesthesiologist. All ablations will be made using PF energy (system FARAPULSE, Boston sci., USA) and under control of intracardiac echocardiography. In contrast to previous work, a total of 20 applications of PF energy will be administered to the mitral isthmus in the first series of ablation. A waiting period of 20 minutes will follow, during which the conduction block across the mitral isthmus will be verified by assessment of the activation sequence on the decapolar catheter in the coronary sinus when pacing from the base of the left atrial appendage and by assessment of the activation of the left atrial appendage when pacing from the distal coronary sinus (or by differential pacing in case of uncertainity). If there is no recurrence of conduction across the mitral isthmus within 20 min, the procedure will be terminated. If recurrence does occur, a second series of 20 PF energy applications will be administered and another 20-minute waiting period will be initiated. In the case of reconduction after the 2nd series, one last optional ablation series will be delivered at the discretion of the operator. For safety reasons, the total waiting time will be 40 minutes and the total number of PF energy applications to the mitral isthmus will be limited to 50 (in the third series, only 10 applications can be delivered). After the procedure, the catheters and sheaths will be withdrawn and the site of puncture fixed with Z suture. All patients will receive 1000 mL of saline postproceduraly and will be endouredged to drink sufficient amount of fluids on the day after the procedure. Renal function (BUN, creatinine) will be assessed on the following day after the procedure.
- Conditions
- Atrial Fibrillation (AF)
- Keywords
- atrial fibrillation, catheter ablation, pulsed-field ablation, mitral isthmus
- Medical subject headings
- Atrial Fibrillation
What is being measured
The primary outcome is the main question the study is designed to answer.
Mitral isthmus block durability after 1 series of PF applications
Acute mitral isthmus conduction block sustained for a waiting period of 20 minutes after 1 series of 20 PF applications
Measured: 20 minutes after last PF application
Secondary outcomes (1)
Overall mitral isthmus block durability
Overall acute mitral isthmus conduction block achieved by the protocol-defined ablation (of up to 3 ablation series of up to 50 PF applications) and sustained for a waiting period of 20 minutes
Measured: 20 minutes after last PF application of last ablation series
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2025
- Study startJan 2025 (estimated)
- Primary completionApr 2025 (estimated)
- Study completionApr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- More trials run by Charles University, Czech RepublicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Charles University, Czech Republic
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06803238
- Sponsor's protocol ID
- FARA Block
- Acronym
- FARA Block
- Status last verified
- Jan 2025
- First submitted
- 27 Jan 2025
- Last updated
- 31 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
Publications
Hornof J, Hozman M, Herman D, Romanenko O, Hassouna S, Vesela J, Filipcova V, Poviser L, Karch J, Hozmanova J, Znojilova L, Molova A, Penkava V, Osmancik P. Acute Efficacy of Pulsed-Field Ablation of the Mitral Isthmus Using a Pentaspline Catheter and Two Different Ablation Settings. J Cardiovasc Electrophysiol. 2026 Feb;37(2):390-399. doi: 10.1111/jce.70236. Epub 2025 Dec 27.
PubMed 41456097
Study at a glance
From the registry record, last updated by the sponsor on 31 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Procedural Mitral Isthmus Block Durability After Pulsed-Field Ablation in Patients with Non-Paroxysmal Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT06803238
- Acronym / sponsor ID
- FARA Block / FARA Block
- Conditions
- Atrial Fibrillation (AF)
- Keywords
- atrial fibrillation, catheter ablation, pulsed-field ablation, mitral isthmus
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Charles University, Czech RepublicUniversity, hospital or other
- Study start
- Jan 2025 (estimated)
- Primary completion
- Apr 2025 (estimated)
- Study completion
- Apr 2025 (estimated)
- First posted
- 31 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mitral isthmus is one of the targets for the catheter ablation of non-paroxysmal atrial fibrillation (AF), in which pulmonary veins isolation alone is not deemed sufficient. Typically, lateral mitral isthmus ablation line is performed from the mitral annulus to the ostium of the left inferior pulmonary vein or to the posterior base of the left atrial appendage. When conduction block across the mitral isthmus is achieved, the standard practice using radiofrequency energy is to wait 20 minutes to verify durability of the conduction block.
Currently, there is an increase in procedures performed using pulsed-field energy (PF). The procedure is in most centers terminated immediately after the energy is delivered, and, unlike radiofrequency energy procedures, there is no waiting period to see if the conduction through the ablation lines returns. However return of conduction across the mitral isthmus has been described during reablation procedures performed for clinical recurrence of arrhythmia (perimitral flutter or atrial fibrillation).
The presented study is a follow-up of previous work, which included 30 patients with non-paroxysmal AF, who underwent PF ablation including mitral isthmus ablation as part of the procedure. Ablation of the mitral isthmus was performed by repeated series of 9 PF energy applications. After each series a waiting period of 20 minutes followed. In case of recurrence of conduction, another series of 9 PF applications was delivered followed by a new waiting period. In the cases of reconduction after the 3rd series, one last series of PF applications was performed, where the number of applications was left at the discretion of the operator, where the total number of applications delivered to the mitral isthmus could not exceed 50. We found that although conduction block on the mitral isthmus was achieved in 90 % of patients after all series, it was only in 33,3 % of patients after the first series. Repeated waiting and multiple ablation series prolonged the procedure unnecessarily. On the other hand, a very high number of pulsed-field energy applications applied initially could be associated with a risk of hemolysis. So far, the number of PF applications up to 80-100 were demonstrated to be safe.
This present study aims to determine whether increasing the number of applications in the first series delivered to the mitral isthmus will be associated with faster and durable achievement of conduction block across the mitral isthmus.
A total of 40 patients with symptomatic non-paroxysmal AF, indicated for catheter ablation according to current guidelines, will be included. Patients with previous left atrial ablation, presenting left ventricular dysfunction with LV EF < 30%, as well as patients at high risk of prolonged analgosedation (i.g. history of severe COPD, treated OSA) will be excluded. The procedure will be performed according to the standards of our center, i.e. pulmonary veins isolation, left atrial posterior wall ablation and mitral isthmus ablation will be performed. All procedures will be performed under analgosedation or general anesthesia controlled by an anesthesiologist. All ablations will be made using PF energy (system FARAPULSE, Boston sci., USA) and under control of intracardiac echocardiography. In contrast to previous work, a total of 20 applications of PF energy will be administered to the mitral isthmus in the first series of ablation. A waiting period of 20 minutes will follow, during which the conduction block across the mitral isthmus will be verified by assessment of the activation sequence on the decapolar catheter in the coronary sinus when pacing from the base of the left atrial appendage and by assessment of the activation of the left atrial appendage when pacing from the distal coronary sinus (or by differential pacing in case of uncertainity). If there is no recurrence of conduction across the mitral isthmus within 20 min, the procedure will be terminated. If recurrence does occur, a second series of 20 PF energy applications will be administered and another 20-minute waiting period will be initiated. In the case of reconduction after the 2nd series, one last optional ablation series will be delivered at the discretion of the operator. For safety reasons, the total waiting time will be 40 minutes and the total number of PF energy applications to the mitral isthmus will be limited to 50 (in the third series, only 10 applications can be delivered). After the procedure, the catheters and sheaths will be withdrawn and the site of puncture fixed with Z suture. All patients will receive 1000 mL of saline postproceduraly and will be endouredged to drink sufficient amount of fluids on the day after the procedure. Renal function (BUN, creatinine) will be assessed on the following day after the procedure.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients referred for catheter ablation of non paroxysmal AF by referring cardiologists and from arrythmology clinic
Key inclusion criteria (1 listed)
- adult patients with symptomatic non-paroxysmal atrial fibrillation indicated for catheter ablation according to the current guidelines
Key exclusion criteria (4 listed)
- Contraindication to catheter ablation according to the current guidelines
- previous left atrial ablation
- left ventricular dysfunction with LV EF < 30%
- Patients at high risk of prolonged analgosedation, e.g. history of severe COPD (stage 3 or 4), obstructive sleep apnea on treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mitral isthmus block durability after 1 series of PF applications
Time frame: 20 minutes after last PF application
Acute mitral isthmus conduction block sustained for a waiting period of 20 minutes after 1 series of 20 PF applications
1 secondary outcome
Overall mitral isthmus block durability
Time frame: 20 minutes after last PF application of last ablation series
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jan 2025.
- Derived from this study: PubMed 41456097Hornof J, Hozman M, Herman D, Romanenko O, Hassouna S, Vesela J, Filipcova V, Poviser L, Karch J, Hozmanova J, Znojilova L, Molova A, Penkava V, Osmancik P. Acute Efficacy of Pulsed-Field Ablation of the Mitral Isthmus Using a Pentaspline Catheter and Two Different Ablation Settings. J Cardiovasc Electrophysiol. 2026 Feb;37(2):390-399. doi: 10.1111/jce.70236. Epub 2025 Dec 27.
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation (AF), run by Charles University, Czech Republic.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pavel Osmancik, prof. MD., Ph.D. (+420267161111, pavel.osmancik@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mitral isthmus block durability after 1 series of PF applications (time frame: 20 minutes after last PF application). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06803238, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2025.